UA96622C2 - Solid dosage forms comprising aliskiren obtained by solvent-free granulation process - Google Patents

Solid dosage forms comprising aliskiren obtained by solvent-free granulation process

Info

Publication number
UA96622C2
UA96622C2 UAA200909671A UAA200909671A UA96622C2 UA 96622 C2 UA96622 C2 UA 96622C2 UA A200909671 A UAA200909671 A UA A200909671A UA A200909671 A UAA200909671 A UA A200909671A UA 96622 C2 UA96622 C2 UA 96622C2
Authority
UA
Ukraine
Prior art keywords
aliskiren
solvent
solid dosage
granulation process
dosage forms
Prior art date
Application number
UAA200909671A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Франц Врецер
Вида Скрабанйа
Наталия Зайц
Урска Гойяк
Original Assignee
Крка, Товарна Здравил, Д.Д., Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крка, Товарна Здравил, Д.Д., Ново Место filed Critical Крка, Товарна Здравил, Д.Д., Ново Место
Publication of UA96622C2 publication Critical patent/UA96622C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates to a pharmaceutical formulation comprising aliskiren or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the pharmaceutical formulation is present in a solid dosage form suitable for oral administration based on a granulate obtained by a hot-melt and solvent-free granulation process, and to a process for manufacturing a pharmaceutical formulation.
UAA200909671A 2007-03-23 2008-03-20 Solid dosage forms comprising aliskiren obtained by solvent-free granulation process UA96622C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07006055A EP1972335A1 (en) 2007-03-23 2007-03-23 Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
UA96622C2 true UA96622C2 (en) 2011-11-25

Family

ID=38006908

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200909671A UA96622C2 (en) 2007-03-23 2008-03-20 Solid dosage forms comprising aliskiren obtained by solvent-free granulation process

Country Status (5)

Country Link
US (1) US20100143460A1 (en)
EP (2) EP1972335A1 (en)
EA (1) EA020331B1 (en)
UA (1) UA96622C2 (en)
WO (1) WO2008116601A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697229A1 (en) * 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of organic compounds
KR20100135970A (en) * 2008-06-06 2010-12-27 테바 파마슈티컬 인더스트리즈 리미티드 Solid states of aliskiren free base
EP2143425A1 (en) * 2008-07-11 2010-01-13 Ratiopharm GmbH Directly pressed aliskiren tablets
AR073651A1 (en) * 2008-09-24 2010-11-24 Novartis Ag GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
EP2340820A1 (en) 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2216020A1 (en) 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
WO2010089105A2 (en) 2009-02-05 2010-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Moisture-activated granulation process
TR201002256A1 (en) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stable aliskiren formulations
EP2382969A1 (en) * 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
CN106620644B (en) * 2016-12-13 2021-05-25 杭州新诺华医药有限公司 Stable perindopril indapamide tablet and preparation process thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003296L (en) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab PROCEDURE SHOULD FORMULATE MEDICINAL PRODUCTS
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
JP5288678B2 (en) * 2002-05-17 2013-09-11 ノバルティス アーゲー Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
EP1782859A3 (en) * 2003-04-11 2009-09-30 High Point Pharmaceuticals, LLC Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines
AR048431A1 (en) * 2004-03-17 2006-04-26 Novartis Ag GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
PE20060362A1 (en) * 2004-05-24 2006-05-15 Irm Llc OXAZOLE COMPOUNDS AS PPAR MODULATORS
PE20060594A1 (en) * 2004-09-09 2006-08-18 Novartis Ag PHARMACEUTICAL COMPOSITION CONTAINING A PPAR AGONIST
CA2580862A1 (en) * 2004-10-08 2006-04-20 Novartis Ag Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
MX2007013471A (en) * 2005-04-27 2008-01-22 Novartis Ag Methods of treating atherosclerosis.
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt

Also Published As

Publication number Publication date
EA020331B1 (en) 2014-10-30
WO2008116601A3 (en) 2009-07-23
EP2136789A2 (en) 2009-12-30
WO2008116601A4 (en) 2009-09-24
EP1972335A1 (en) 2008-09-24
WO2008116601A2 (en) 2008-10-02
EA200901146A1 (en) 2009-12-30
US20100143460A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
UA96622C2 (en) Solid dosage forms comprising aliskiren obtained by solvent-free granulation process
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
HRP20160327T1 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
IL197393A (en) Pyridin-4-yl derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for treatment of diseases associated with the immune system
WO2012020097A3 (en) Use of binders for manufacturing storage stable formulations
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2007014124A3 (en) High drug load formulations and dosage forms
MX347135B (en) Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof.
WO2005107721A3 (en) Pharmaceutical dosage form comprising pellets as well as its manufacturing process
WO2008023016A3 (en) Galenic formulations of aliskiren
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2010097243A3 (en) Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
WO2008093075A3 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
MX340188B (en) Manufacturing of active-free granules and tablets comprising the same.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EP2316420A8 (en) Method to reduce pain
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
UA95274C2 (en) Solid pharmaceutical composition comprising irbesartan and processes for the manufacture thereof
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
HRP20060079A2 (en) Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
WO2009040373A3 (en) Galenical formulations of aliskiren